



PHARMA FOODS INTERNATIONAL CO.,LTD.

Company Name: Pharma Foods International Co., Ltd.

Representative: President & CEO, Mujo Kim

Stock Exchange Market: Tokyo Prime (2929)

Head Office: 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto 615-8245

Contact Number: +81-75-394-8600

News Release

April 6, 2026

Pharma Foods Co., Ltd. Acquires Exclusive Rights to Advance First-in-Class Adrenomedullin Program for CADASIL Across Key Asian Markets

Pharma Foods Co., Ltd. (Head Office: Kyoto, Japan; President and CEO: Mujo Kim; hereinafter “the Company”) announced that it has entered into exclusive licensing agreements with Himuka AM Pharma Corp. (Head Office: Miyazaki, Japan) and the National Cerebral and Cardiovascular Center (Osaka, Japan; hereinafter: “NCVC”) to develop and commercialize human adrenomedullin as a potential first-in-class therapy for CADASIL.

Under the terms of the agreements, the Company has secured exclusive rights to intellectual property and clinical data covering adrenomedullin for CADASIL in Japan, South Korea, and Taiwan. The Company intends to leverage this foundation to accelerate clinical development and establish a leading position in this underserved indication.

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a rare, progressive cerebrovascular disease with no approved disease-modifying therapies, representing a significant unmet medical need. Adrenomedullin is a vasoactive peptide with well-characterized biological activity, originally discovered by Dr. Kazuo Kitamura, Dr. Kenji Kangawa, and colleagues, and has demonstrated promising signals in prior academic-led clinical research conducted at NCVC.

We intend to advance this program toward clinical and regulatory milestones, with the goal of delivering a differentiated therapeutic option for patients while unlocking long-term shareholder value. This program is expected to become a core asset within our expanding pharmaceutical pipeline.

Mujo Kim, President and CEO, commented:

“We are excited to secure exclusive rights to advance adrenomedullin as a potential first-in-class therapy for CADASIL. This program aligns with our strategy to build a pipeline focused on high-impact, underserved indications supported by strong scientific rationale and clinical insight. We believe this asset has the potential to create significant value, and we are committed to rapidly advancing its development in collaboration with leading academic and clinical partners.”

The impact on the Company’s financial results for the current fiscal year is expected to be limited. However, the program is anticipated to represent a meaningful growth driver over the

medium to long term. The Company will provide updates on clinical progress and key milestones as they are achieved.

【Adrenomedullin】

Adrenomedullin is an endogenous peptide hormone known to exhibit a range of physiological activities, including vasodilation, anti-inflammatory effects, and endothelial protection. While research has primarily focused on cardiovascular diseases, its potential therapeutic applications are also being explored in other conditions, including cerebral small vessel diseases.

【CADASIL】

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is an inherited small vessel disease of the brain triggered by NOTCH3 gene mutations, often leading to premature strokes and progressive cognitive decline. In Japan, it is officially recognized as a designated intractable disease, with an estimated prevalence of 1.20 to 3.58 per 100,000 adults. As no definitive curative treatment exists to date, this condition represents a significant unmet medical need, making the development of an effective therapy a critical priority for both patients and the medical community.

【Himuka AM Pharma Corp.】

Himuka AM Pharma Corp. is a biopharmaceutical company originating from the University of Miyazaki, focused on drug discovery. Through the development and licensing of adrenomedullin, the company aims to create new therapeutic options for diseases with high unmet medical needs.

【The National Cerebral and Cardiovascular Center (NCVC)】

NCVC is a National Research and Development Agency dedicated to overcoming cardiovascular and cerebrovascular diseases. It maintains a seamless research framework that spans from foundational studies to clinical research, spearheading cutting-edge research and advanced medical care in these specialized fields.

For inquiries regarding this announcement, please contact us via the Company's inquiry form:

<https://www.pharmafoods.co.jp/contact/biomedical>